Tromboze greft arteryovenöz fistülü olan hastalarda arrow-trerotola cihazi ile perküten mekanik trombektomi

Tromboze arteryovenöz fistülü olan hemodiyaliz hastalarında perkütan mekanik trombektomi işleminde kullanılan Arrow-Trerotola cihazının etkinliğinin ve güvenilirliğinin araştırılması. GEREÇ VE YÖNTEM Greft fistül oklüzyonu olan 10 hastaya Arrow-Trerotola cihazı ile perkütan mekanik trombektomi işlemi yapıldı. 10 hastaya toplam 13 kez işlem uyglandı. Teknik başarı, komplikasyonlar, primer ve sekonder açık kalım oranları değerlendirildi. Teknik başarı oranı %84 idi (13 işlemin 11'inde). Hastaların hiç birisinde majör komplikasyon izlenmedi. Ortalama takip süresi 8,5 ay idi. Yedi hastada greft fistüller hala patenttir. Bu 7 hastanın 3'ünde patensinin devamı için ek işlemler uygulandı. Üç aylık primer ve sekonder açık kalım oranları sırasıyla %66 ve %77 olarak hesaplandı. SONUÇ Arrow-Trerotola perkütan mekanik trombektomi cihazı tromboze hemodiyaliz greftlerinin tedavisinde kullanılan etkili bir yöntemdir. To assess the safety and efficacy of the Arrow-Trerotola percutaneous thrombectomy device in the treatment of thrombosed hemodialysis access grafts in dialysis patients. MATERIALS AND METHODS: Ten patients with graft fistula occlusion underwent mechanical thrombectomy with Arrow-Trerotola percutaneous thrombectomy device. Thirteen trombectomy procedures were performed in ten patients. Technical success, complications, primary and secondary patency rates were noted. RESULTS: The technical success rate was 84% (11 of 13 procedures). There were no major complications. The mean follow-up period was 8,5 months. The graft fistula are still functional in seven patients. In 3 of 7 patients, additional procedures were needed for patency. The 3-month primary and secondary patency rates were 66% and 77% respectively. CONCLUSION: Percutaneous mechanical thrombectomy with the Arrow-Trerotola device is an effective method for the treatment of the thrombosed hemodialysis grafts

COVID-19 associated multisystemic inflammatory syndrome in 614 children with and without overlap with Kawasaki disease-Turk MIS-C study group.

Multisystemic inflammatory syndrome (MIS-C) diagnosis remains difficult because the clinical features overlap with Kawasaki disease (KD). The study aims to highlight the clinical and laboratory features and outcomes of patients with MISC whose clinical manifestations overlap with or without KD. This study is a retrospective analysis of a case series designed for patients aged 1 month to 18 years in 28 hospitals between November 1, 2020, and June 9, 2021. Patient demographics, complaints, laboratory results, echocardiographic results, system involvement, and outcomes were recorded. A total of 614 patients were enrolled; the median age was 7.4 years (interquartile range (IQR) 3.9-12 years). A total of 277 (45.1%) patients with MIS-C had manifestations that overlapped with KD, including 92 (33.3%) patients with complete KD and 185 (66.7%) with incomplete KD. Lymphocyte and platelet counts were significantly lower in patients with MISC, overlapped with KD (lymphocyte count 1080 vs. 1280 cells x mu L, p = 0.028; platelet count 166 vs. 216 cells x 10(3)/mu L, p 12 years reduced the risk of overlap with KD by 66% (p < 0.001, 95% CI 0.217-0.550), lethargy increased the risk of overlap with KD by 2.6-fold (p = 0.011, 95% CI 1.244-5.439), and each unit more albumin (g/dl) reduced the risk of overlap with KD by 60% (p < 0.001, 95% CI 0.298-0.559)

Epidemiological, Clinical, and Laboratory Features of Children With COVID-19 in Turkey

Objectives: The aim of this study is to identify the epidemiological, clinical, and laboratory features of coronavirus disease 2019 (COVID-19) in children